Table 6.
Baseline characteristics and use of HT post stopping in women who completed both pre-stopping post-stopping HT use questionnaires (n =3496)
| Currently take prescription and non-prescription hormones (n=13) | Currently take prescription hormones (n=141) | Currently take natural (non-prescription) hormones (n=127) | No current hormone use (n=3119) | P-Value36 | |||||
|---|---|---|---|---|---|---|---|---|---|
| N | % | N | % | N | % | N | % | ||
| HT Use | |||||||||
| Placebo | 1 | 7.7 | 30 | 21.3 | 54 | 42.5 | 1639 | 52.5 | <0.001 |
| CEE | 12 | 92.3 | 111 | 78.7 | 73 | 57.5 | 1480 | 47.5 | |
| Moderate/severe vasomotor symptoms | |||||||||
| No | 10 | 76.9 | 103 | 73.2 | 96 | 75.2 | 2658 | 85.2 | <0.001 |
| Yes | 3 | 23.1 | 38 | 26.8 | 31 | 24.8 | 461 | 14.8 | |
| HT Usage Status at Baseline | |||||||||
| Never used | 5 | 38.5 | 53 | 37.6 | 48 | 37.8 | 1536 | 49.3 | <0.001 |
| Past user | 0 | 0.0 | 43 | 30.5 | 42 | 33.1 | 1133 | 36.3 | |
| Current user | 8 | 61.5 | 45 | 31.9 | 37 | 29.1 | 448 | 14.4 | |
36
Chi-squared test of association.